Zobrazeno 1 - 10
of 2 954
pro vyhledávání: ''
Publikováno v:
Annals of Oncology. 31:1135-1147
Background Colorectal cancer (CRC) represents a major cause of cancer deaths worldwide. Although significant progress has been made by molecular and immune therapeutic approaches, prognosis of advanced stage disease is still dismal. Alterations in th
Autor:
Jenny F. Seligmann, Bart Jacobs, Gemma Hemmings, Philip Quirke, Susan D. Richman, Christopher Williams, Sarah Brown, Faye Elliott, Matthew T. Seymour, Sabine Tejpar, Jennifer H. Barrett
Publikováno v:
Annals of Oncology. 31:1021-1029
BACKGROUND: Primary tumour location (PTL) is being adopted by clinicians to guide treatment decisions in metastatic colorectal cancer (mCRC). Here we test PTL as a predictive marker for panitumumab efficacy, and examine its relationship with an exten
Publikováno v:
Annals of Oncology. 31:558-568
Background Aspirin has been associated with a reduced risk of colorectal cancer, and possibly of a few other digestive tract cancers. The quantification of risk reduction and the optimal dose and duration of aspirin use for the prevention of colorect
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Universidad de Barcelona
Background: We conducted a systematic literature review and meta-analysis of observational studies investigating adherence to the 2007 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) lifestyle recommendations for cancer
Autor:
Tobias Heintges, J. C. von Einem, Swantje Held, Christoph Kahl, Florian Kaiser, Marlies Michl, Alexander Kiani, Werner Scheithauer, L. Fischer von Weikersthal, Markus Moehler, Volker Heinemann, Frank Kullmann, Thomas Decker, Julian Walter Holch, Sebastian Stintzing
Publikováno v:
Annals of Oncology. 31:72-78
Background Cetuximab-induced skin toxicity (Cet-ST) is positively associated with outcome in metastatic colorectal cancer (mCRC). Besides its predictive relevance for targeted therapy, we investigated its prognostic impact with early tumor shrinkage
Autor:
Sebastian Stintzing, Dominik Paul Modest, Volker Heinemann, T. Kirchner, Alexander Kiani, Andreas Jung, Dan Aderka, Thomas Decker, Frank Kullmann, L. Fischer von Weikersthal, Werner Scheithauer, Pratyaksha Wirapati, Tobias Heintges, Christian A. Lerchenmuller, H. J. Lenz, Daniel Neureiter, Markus Moehler, G. Seipelt, Sabine Tejpar, Christoph Kahl, S-E. Al-Batran, Swantje Held, Florian Kaiser
Publikováno v:
Annals of Oncology
BACKGROUND: FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping CRC samples according to
Autor:
Axel Grothey, Rachel Kerr, A. de Gramont, Takayuki Yoshino, Thierry André, Julien Taieb, Greg Yothers, Q. Shi, E. Van Cutsem, Aziz Zaanan, Steven R. Alberts, Levi Pederson, Sara Lonardi, Norman Wolmark, Frank A. Sinicrope
Publikováno v:
Annals of Oncology. 30:1466-1471
Microsatellite instable/deficient mismatch repair (MSI/dMMR) metastatic colorectal cancers have been reported to have a poor prognosis. Frequent co-occurrence of MSI/dMMR and BRAFV600E complicates the association.Patients with resected stage III colo
Autor:
M.K. Fink
Publikováno v:
Annals of Oncology
Autor:
H. J. Lenz, T. Yoshino
Publikováno v:
Annals of Oncology. 31:1085-1087
Publikováno v:
Annals of Oncology
TNM staging alone does not accurately predict outcome in colon cancer (CC) patients who may be eligible for adjuvant chemotherapy. It is unknown to what extent the molecular markers microsatellite instability (MSI) and mutations in BRAF or KRAS impro